BACKGROUND: This study utilizes a four-level pyramid framework to understand the relationship between symptom reports and/or abnormal pulmonary function and diagnoses of airway diseases (AD), including asthma, recurrent bronchitis and COPD/emphysema in WTC-exposed firefighters. We compare the distribution of pyramid levels at two time-points: by 9/11/2005 and by 9/11/2010. METHODS: We studied 6,931 WTC-exposed FDNY firefighters who completed a monitoring exam during the early period and at least two additional follow-up exams 9/11/2005-9/11/2010. RESULTS: By 9/11/2005 the pyramid structure was as follows: 4,039 (58.3%) in Level 1, no respiratory evaluation or treatment; 1,608 (23.2%) in Level 2, evaluation or treatment without AD diagnosis; 1,005 (14.5%) in Level 3, a single AD diagnosis (asthma, emphysema/COPD, or recurrent bronchitis); 279 (4.0%) in Level 4, asthma and another AD. By 9/11/2010, the pyramid distribution changed considerably, with Level 1 decreasing to 2,612 (37.7% of the cohort), and Levels 3 (N = 1,530) and 4 (N = 796) increasing to 22.1% and 11.5% of the cohort, respectively. Symptoms, spirometry measurements and healthcare utilization were associated with higher pyramid levels. CONCLUSIONS: Respiratory diagnoses, even four years after a major inhalation event, are not the only drivers of future healthcare utilization. Symptoms and abnormal FEV-1 values must also be considered if clinicians and healthcare administrators are to accurately anticipate future treatment needs, years after initial exposure.
BACKGROUND: This study utilizes a four-level pyramid framework to understand the relationship between symptom reports and/or abnormal pulmonary function and diagnoses of airway diseases (AD), including asthma, recurrent bronchitis and COPD/emphysema in WTC-exposed firefighters. We compare the distribution of pyramid levels at two time-points: by 9/11/2005 and by 9/11/2010. METHODS: We studied 6,931 WTC-exposed FDNY firefighters who completed a monitoring exam during the early period and at least two additional follow-up exams 9/11/2005-9/11/2010. RESULTS: By 9/11/2005 the pyramid structure was as follows: 4,039 (58.3%) in Level 1, no respiratory evaluation or treatment; 1,608 (23.2%) in Level 2, evaluation or treatment without AD diagnosis; 1,005 (14.5%) in Level 3, a single AD diagnosis (asthma, emphysema/COPD, or recurrent bronchitis); 279 (4.0%) in Level 4, asthma and another AD. By 9/11/2010, the pyramid distribution changed considerably, with Level 1 decreasing to 2,612 (37.7% of the cohort), and Levels 3 (N = 1,530) and 4 (N = 796) increasing to 22.1% and 11.5% of the cohort, respectively. Symptoms, spirometry measurements and healthcare utilization were associated with higher pyramid levels. CONCLUSIONS: Respiratory diagnoses, even four years after a major inhalation event, are not the only drivers of future healthcare utilization. Symptoms and abnormal FEV-1 values must also be considered if clinicians and healthcare administrators are to accurately anticipate future treatment needs, years after initial exposure.
Authors: Gisela I Banauch; Dawn Alleyne; Raoul Sanchez; Kattia Olender; Hillel W Cohen; Michael Weiden; Kerry J Kelly; David J Prezant Journal: Am J Respir Crit Care Med Date: 2003-02-25 Impact factor: 21.405
Authors: Gabriel Izbicki; Robert Chavko; Gisela I Banauch; Michael D Weiden; Kenneth I Berger; Thomas K Aldrich; Charles Hall; Kerry J Kelly; David J Prezant Journal: Chest Date: 2007-03-30 Impact factor: 9.410
Authors: Michael D Weiden; Natalia Ferrier; Anna Nolan; William N Rom; Ashley Comfort; Jackson Gustave; Rachel Zeig-Owens; Shugi Zheng; Roberta M Goldring; Kenneth I Berger; Kaitlyn Cosenza; Roy Lee; Mayris P Webber; Kerry J Kelly; Thomas K Aldrich; David J Prezant Journal: Chest Date: 2009-10-09 Impact factor: 9.410
Authors: Sydney Chiu; Mayris P Webber; Rachel Zeig-Owens; Jackson Gustave; Roy Lee; Kerry J Kelly; Linda Rizzotto; Rita McWilliams; John K Schorr; Carol S North; David J Prezant Journal: Ann Clin Psychiatry Date: 2011-05 Impact factor: 1.567
Authors: Mayris P Webber; Michelle S Glaser; Jessica Weakley; Jackie Soo; Fen Ye; Rachel Zeig-Owens; Michael D Weiden; Anna Nolan; Thomas K Aldrich; Kerry Kelly; David Prezant Journal: Am J Ind Med Date: 2011-09 Impact factor: 2.214
Authors: Mayris P Webber; Jackson Gustave; Roy Lee; Justin K Niles; Kerry Kelly; Hillel W Cohen; David J Prezant Journal: Environ Health Perspect Date: 2009-02-11 Impact factor: 9.031
Authors: Sydney Chiu; Mayris P Webber; Rachel Zeig-Owens; Jackson Gustave; Roy Lee; Kerry J Kelly; Linda Rizzotto; David J Prezant Journal: J Affect Disord Date: 2009-06-18 Impact factor: 4.839
Authors: Juan P Wisnivesky; Susan L Teitelbaum; Andrew C Todd; Paolo Boffetta; Michael Crane; Laura Crowley; Rafael E de la Hoz; Cornelia Dellenbaugh; Denise Harrison; Robin Herbert; Hyun Kim; Yunho Jeon; Julia Kaplan; Craig Katz; Stephen Levin; Ben Luft; Steven Markowitz; Jacqueline M Moline; Fatih Ozbay; Robert H Pietrzak; Moshe Shapiro; Vansh Sharma; Gwen Skloot; Steven Southwick; Lori A Stevenson; Iris Udasin; Sylvan Wallenstein; Philip J Landrigan Journal: Lancet Date: 2011-09-03 Impact factor: 202.731
Authors: Katherine Wheeler; Wendy McKelvey; Lorna Thorpe; Megan Perrin; James Cone; Daniel Kass; Mark Farfel; Pauline Thomas; Robert Brackbill Journal: Environ Health Perspect Date: 2007-11 Impact factor: 9.031
Authors: Rachel Zeig-Owens; Anna Nolan; Barbara Putman; Ankura Singh; David J Prezant; Michael D Weiden Journal: Am J Ind Med Date: 2016-09 Impact factor: 2.214
Authors: Michael D Weiden; Sophia Kwon; Erin Caraher; Kenneth I Berger; Joan Reibman; William N Rom; David J Prezant; Anna Nolan Journal: Semin Respir Crit Care Med Date: 2015-05-29 Impact factor: 3.119
Authors: Thomas K Aldrich; Jessica Weakley; Sean Dhar; Charles B Hall; Tesha Crosse; Gisela I Banauch; Michael D Weiden; Gabriel Izbicki; Hillel W Cohen; Aanchal Gupta; Camille King; Vasilios Christodoulou; Mayris P Webber; Rachel Zeig-Owens; William Moir; Anna Nolan; Kerry J Kelly; David J Prezant Journal: Chest Date: 2016-07-19 Impact factor: 9.410
Authors: Justin K Niles; Mayris P Webber; Xiaoxue Liu; Rachel Zeig-Owens; Charles B Hall; Hillel W Cohen; Michelle S Glaser; Jessica Weakley; Theresa M Schwartz; Michael D Weiden; Anna Nolan; Thomas K Aldrich; Lara Glass; Kerry J Kelly; David J Prezant Journal: Am J Ind Med Date: 2014-06-04 Impact factor: 2.214
Authors: Sophia Kwon; George Crowley; Mena Mikhail; Rachel Lam; Emily Clementi; Rachel Zeig-Owens; Theresa M Schwartz; Mengling Liu; David J Prezant; Anna Nolan Journal: Int J Environ Res Public Health Date: 2019-04-26 Impact factor: 3.390
Authors: Deepak Pradhan; Ning Xu; Joan Reibman; Roberta M Goldring; Yongzhao Shao; Mengling Liu; Kenneth I Berger Journal: Int J Environ Res Public Health Date: 2019-04-20 Impact factor: 3.390